Results 131 to 140 of about 47,203 (289)

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr   +10 more
wiley   +1 more source

Fluorescence of cannabinoids

open access: yesJournal of Pharmacy and Pharmacology, 1975
DIONYSSIOUASTER.A, MIRAS, CJ
openaire   +3 more sources

Medical cannabinoids [PDF]

open access: yesCanadian Medical Association Journal, 2017
Scott A, McLeod, Jean-François, Lemay
openaire   +2 more sources

A Discount on Cannabinoids

open access: yesBiological Psychiatry, 2014
Signs posted in coffee shops throughout California warn their readers that “chemicals known to cause cancer and reproductive toxicity are present in coffee, baked goods and other foods or beverages sold here.” Undeterred by the admonition, every day millions of Californians eat their morning muffin accompanied by a hefty coffee drink.
openaire   +4 more sources

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Synthetic cannabinoids [PDF]

open access: yesCanadian Medical Association Journal, 2013
Tony, Antoniou, David N, Juurlink
openaire   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade   +7 more
wiley   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy